Stock Traders Purchase High Volume of Call Options on Tempus AI (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) was the recipient of some unusual options trading activity on Monday. Investors bought 34,007 call options on the company. This represents an increase of approximately 11% compared to the typical volume of 30,644 call options.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TEM shares. Canaccord Genuity Group upped their target price on shares of Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. UBS Group started coverage on Tempus AI in a research note on Wednesday, September 9th. They set a “neutral” rating and a $70.00 price objective on the stock. HC Wainwright boosted their target price on shares of Tempus AI from $68.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, Jefferies Financial Group upgraded shares of Tempus AI from an “underperform” rating to a “hold” rating and increased their price objective for the stock from $35.00 to $70.00 in a report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Tempus AI presently has an average rating of “Hold” and an average price target of $79.37.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus reported Q3 revenue of $411.5 million, up 23.1% year over year and ahead of expectations. Adjusted earnings of $0.07 per share also beat estimates, which had called for a loss. Tempus AI Surges on Earnings Beat, But Can the Rally Last?
• Positive Sentiment: The company raised its 2026 revenue outlook to $1.60 billion–$1.605 billion and is targeting about $65 million in adjusted EBITDA. Investors are also looking to oncology demand, data partnerships, and reimbursement-related pricing gains as potential growth drivers into 2027. Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
• Positive Sentiment: Several analysts raised price targets after the results: Baird and Cantor Fitzgerald moved to $92, while HC Wainwright raised its target to $85; all maintained positive ratings. Baird analyst recommendations
• Neutral Sentiment: Some coverage cautions that the stock may already reflect much of its recent rally, limiting near-term upside. UBS reiterated a Hold rating with an $80 target. Tempus AI Stock Looks Fully Priced Following Its 26% Run
• Negative Sentiment: Risks include continued cash burn, weaker hereditary-testing performance, and execution challenges related to the proposed Personalis acquisition, which could weigh on results if integration proves difficult. Integration Risks Loom Over Tempus AI’s Proposed Personalis Acquisition

Tempus AI Stock Down 0.9%

Shares of NASDAQ TEM opened at $77.80 on Wednesday. Tempus AI has a 1 year low of $40.77 and a 1 year high of $89.09. The firm has a market cap of $14.04 billion, a price-to-earnings ratio of -73.40 and a beta of 3.61. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The stock’s 50-day simple moving average is $71.04 and its 200-day simple moving average is $57.17.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative return on equity of 48.29% and a negative net margin of 12.54%. The business had revenue of $411.54 million for the quarter, compared to analysts’ expectations of $409.39 million. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. The company’s revenue was up 23.1% compared to the same quarter last year. As a group, equities analysts anticipate that Tempus AI will post -1.45 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In other news, CAO Ryan M. Bartolucci sold 7,062 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $529,650.00. Following the completion of the transaction, the chief accounting officer directly owned 60,804 shares of the company’s stock, valued at approximately $4,560,300. This represents a 10.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $69.00, for a total value of $207,000.00. Following the completion of the sale, the director directly owned 31,981 shares of the company’s stock, valued at $2,206,689. This represents a 8.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,256,777 shares of company stock valued at $86,356,352 over the last 90 days. Insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently made changes to their positions in TEM. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares during the period. Amova Asset Management Americas Inc. lifted its position in shares of Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in shares of Tempus AI by 2,965.7% in the 3rd quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock valued at $41,233,000 after buying an additional 486,493 shares during the period. Eagle Health Investments LP acquired a new position in shares of Tempus AI in the 1st quarter valued at about $11,588,000. Finally, Washington Trust Advisors Inc. boosted its holdings in shares of Tempus AI by 35.7% in the 3rd quarter. Washington Trust Advisors Inc. now owns 121,039 shares of the company’s stock valued at $9,913,000 after buying an additional 31,873 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.